Effect of Symbicort on Sleep Quality in Patients With Emphysema

Status Active, not recruiting

Clinical Trial Summary

This study will look at the effects of the drug Symbicort on sleep quality. Symbicort is an inhaled medication that contains 2 drugs. One is a medication that opens up the airways (formoterol). The other is a steroid to decrease airway inflammation (budesonide). Symbicort is not an experimental medication. It is approved by the Food and Drug Administration for use in patients with emphysema. Patients with severe emphysema commonly sleep poorly. The cause of poor sleep in these patients is unknown. Symbicort may improve sleep quality by opening the airways and reducing lung inflammation. It is not known for sure if these effects actually improve sleep and quality of life. It is hoped that this study will answer this question.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01602523
Study type	Interventional
Source	Temple University
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	March 2011
Completion date	August 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05825261` - Exploring Novel Biomarkers for Emphysema Detection
Completed	`NCT02914340` - REACH SVS Control Patient Cross-Over Study	N/A
Completed	`NCT02999685` - Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients	N/A
Completed	`NCT02232841` - Electrical Impedance Imaging of Patients on Mechanical Ventilation	N/A
Completed	`NCT02238327` - Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
Withdrawn	`NCT01908933` - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema	Phase 3
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT01710449` - Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen	Phase 1
Suspended	`NCT00523094` - Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure	N/A
Completed	`NCT00475007` - Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema	N/A
Recruiting	`NCT00129350` - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation	Phase 1
Completed	`NCT01953523` - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions	N/A
Completed	`NCT00000621` - Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)	Phase 2
Completed	`NCT00005292` - Alpha1-antitrypsin Deficiency Registry	N/A
Recruiting	`NCT04537182` - Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema	N/A
Active, not recruiting	`NCT02713347` - Advancing Symptom Alleviation With Palliative Treatment	N/A
Recruiting	`NCT04302272` - STRIVE Post-Market Registry Study
Completed	`NCT04435327` - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed	`NCT03636347` - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.	Phase 2